NCT06485635Completed
Real-life-persistence to Antifibrotic Treatments
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment. Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 10646 (actual)
- First submitted
- 10 Jun 2024
- Start date
- 16 Oct 2024
- Primary completion date
- 7 Apr 2026
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT06485635
What you commit to
- Study type: Observational
- Participants enrolled: 10646
- From 16 Oct 2024 to the primary completion date, 7 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No exclusion criteria will be applied.
Who the study is looking for
- All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinityx Coordinator of this site? Confirm its status | Boulogne-Billancourt | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.